(HealthDay News) – For patients with psoriasis, major medical comorbidity increases with increasing severity of disease, according to a study published online Aug. 7 in JAMA Dermatology.
Howa Yeung, from the University of Pennsylvania Perelman School of Medicine in Philadelphia, and colleagues conducted a population-based cross-sectional study of patient data from U.K.-based electronic medical records to examine the prevalence of major medical comorbidity in patients with mild, moderate, or severe psoriasis. The analysis included 9,035 patients with psoriasis, aged 25–64 years, and 90,350 age- and practice-matched controls without psoriasis.
Of the patients with psoriasis, 51.8% had mild disease, 35.8% had moderate disease, and 12.4% had severe disease. The researchers found that the mean Charlson comorbidity index was increasingly higher for patients with increasing severity of psoriasis. Overall, psoriasis was associated with significantly increased prevalence of chronic pulmonary disease (adjusted odds ratio [aOR], 1.08), diabetes mellitus and diabetes with systemic complications (aOR, 1.22 and 1.34, respectively), mild liver disease (aOR, 1.41), myocardial infarction (aOR, 1.34), peptic ulcer disease (aOR, 1.27), peripheral vascular disease (aOR, 1.38), renal disease (aOR, 1.28), and rheumatologic disease (aOR, 2.04). For each of the comorbidities, significant associations were observed for psoriasis severity.
“The burdens of overall medical comorbidity and of specific comorbid diseases increase with increasing disease severity among patients with psoriasis,” the authors write. “Physicians should be aware of these associations in providing comprehensive care to patients with psoriasis, especially those presenting with more severe disease.”
Two authors disclosed financial ties to the pharmaceutical industry.